Concepedia

Kenneth C. Rupert

KC

Statistics

Publications

11

Citations

575

H-Index

11

Active since

1998

Affiliations

Johnson & Johnson (United States)(Current)

Drug Discovery Laboratory (Norway)

Kenneth C. Rupert is an author at Johnson & Johnson (United States) specializing in pharmacology, medicinal chemistry, and molecular pharmacology.

Publications per year

1998–2013

11

Publications

11

Imidazopyrimidines, potent inhibitors of p38 MAP kinase

Kenneth C. Rupert, James R. Henry, John H. Dodd et al. · Bioorganic & Medicinal Chemistry Letters · 2003 · 252 citations · Full text

, , +9

6-Amino-2-(4-fluorophenyl)-4-methoxy-3- (4-pyridyl)-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridine (RWJ 68354):  A Potent and Selective p38 Kinase Inhibitor

James R. Henry, Kenneth C. Rupert, John H. Dodd et al. · Journal of Medicinal Chemistry · 1998 · 77 citations · Full text

, , +5

In Vivo Characterization of a Dual Adenosine A<sub>2A</sub>/A<sub>1</sub> Receptor Antagonist in Animal Models of Parkinson’s Disease

Brian C. Shook, Stefanie Rassnick, Melville C. Osborne et al. · Journal of Medicinal Chemistry · 2010 · 54 citations · Full text

, , +14

Potent inhibitors of the MAP kinase p38

James R. Henry, Kenneth C. Rupert, John H. Dodd et al. · Bioorganic & Medicinal Chemistry Letters · 1998 · 43 citations · Full text

, , +10

Optimization of Benzodiazepinones as Selective Inhibitors of the X-Linked Inhibitor of Apoptosis Protein (XIAP) Second Baculovirus IAP Repeat (BIR2) Domain

Robert F. Kester, Andrew F. Donnell, Yan Lou et al. · Journal of Medicinal Chemistry · 2013 · 38 citations · Full text

, , +16

1–5 of 11